Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENHERTU vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Unresectable or metastatic HER2-positive breast cancer after prior anti-HER2-based regimen in metastatic setting,Metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer after prior chemotherapy in metastatic setting,Unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after prior trastuzumab-based regimen,HER2-positive non-small cell lung cancer with activating HER2 mutation after prior systemic therapy,HER2-positive solid tumors (tumor agnostic) after prior systemic therapy and no satisfactory alternative
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is approximately 5.5 days (range 4.5–7.5 days) for the antibody-drug conjugate, supporting every-3-week dosing.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
DXd, the released payload, is primarily metabolized by CYP3A4.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily biliary/fecal excretion (approximately 95% as unchanged drug); renal excretion is negligible (<1%).
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Trastuzumab deruxtecan: Approximately 99% bound to plasma proteins (primarily to albumin).
82–88% bound to plasma proteins (primarily albumin).
Approximately 10–12 L (approx. 0.14–0.17 L/kg for a 70 kg adult), indicating distribution primarily in vascular space.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Not applicable; administered intravenously (100% bioavailability).
Oral: 65–80% (median 73%)
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). No data for severe renal impairment (Cr Cl <30 m L/min).
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 4.4 mg/kg. Child-Pugh C: Not recommended.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and efficacy not established; no recommended dose.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment. Monitor for toxicity, especially in patients aged ≥65 years due to limited data.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY. Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have occurred. Monitor for signs and symptoms of ILD and withhold, dose reduce, or permanently discontinue based on severity. Exposure during pregnancy can cause embryo-fetal harm; advise patients of these risks.
None
Interstitial lung disease/pneumonitis,Left ventricular ejection fraction (LVEF) reduction,Neutropenia,Fever, infection, or thrombocytopenia,Embryo-fetal toxicity
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
None listed.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No specific food interactions are known; however, ENHERTU may cause nausea, vomiting, and diarrhea. Patients should avoid heavy, spicy, or fatty foods if gastrointestinal side effects occur and maintain adequate hydration.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of trastuzumab deruxtecan to pregnant rats during organogenesis resulted in embryofetal toxicity including decreased fetal weight and increased fetal malformations at exposures below the recommended human dose based on AUC. Due to the potential for genotoxicity and inhibition of rapidly dividing cells, there is a high teratogenic risk, particularly during the first trimester. During second and third trimesters, fetal growth restriction and oligohydramnios may occur due to HER2 receptor inhibition, although the deruxtecan component primarily drives toxicity. Effective contraception should be used during treatment and for at least 7 months after the last dose.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
There are no data on the presence of trastuzumab deruxtecan in human milk, its effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 7 months after the last dose. The M/P ratio is unknown.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
There are no specific dose adjustment guidelines for ENHERTU during pregnancy. The recommended dose is 5.4 mg/kg as an intravenous infusion every 3 weeks. Pregnancy may alter drug pharmacokinetics due to increased plasma volume, reduced albumin, changes in hepatic metabolism and renal clearance. However, no pharmacokinetic studies have been conducted in pregnant women. Therefore, the standard dosing should be used with caution, and clinical judgment should be applied based on maternal and fetal monitoring. Dose reductions or delays may be considered if significant toxicities (e.g., ILD, neutropenia, hepatic impairment) occur. Due to the high risk of fetal harm, use in pregnancy is not recommended unless the maternal benefit justifies the risk.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Monitor for interstitial lung disease (ILD) and pneumonitis; withhold ENHERTU for grade 1 ILD and permanently discontinue for grade 2 or higher. Assess left ventricular ejection fraction (LVEF) before and during treatment; withhold for any grade of reduction. Premedicate with antiemetics per institutional guidelines. Do not substitute with trastuzumab or ado-trastuzumab emtansine.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Report new or worsening cough, shortness of breath, or fever immediately as these may be signs of lung problems.,Notify your doctor of any nausea, vomiting, diarrhea, or constipation as these can be managed with medications.,Avoid pregnancy during treatment and for 7 months after last dose; use effective contraception.,Do not breastfeed during treatment and for 1 month after last dose.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENHERTU vs AGRYLIN, answered by our medical review team.
ENHERTU is a Antineoplastic Agent that works by Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate (ADC). The antibody is a humanized anti-HER2 Ig G1, and the small molecule DXd is a topoisomerase I inhibitor. Upon binding to HER2 on tumor cells, the ADC undergoes internalization and intracellular cleavage, releasing DXd which causes DNA damage and apoptotic cell death.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENHERTU and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENHERTU is: 5.4 mg/kg intravenously every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENHERTU and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENHERTU is classified as Category C. Based on its mechanism of action (topoisomerase I inhibitor) and animal studies, trastuzumab deruxtecan is expected to cause fetal harm when administered to a pregnant woman. There. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.